| Literature DB >> 18331636 |
Laurence Flori1, Claire Rogel-Gaillard, Marielle Cochet, Gaetan Lemonnier, Karine Hugot, Patrick Chardon, Stéphane Robin, François Lefèvre.
Abstract
BACKGROUND: Transcriptomic approaches are relevant for studying virus-host cell dialogues to better understand the physiopathology of infection and the immune response at the cellular level. Pseudorabies virus (PrV), a porcine Alphaherpesvirus, is a good model for such studies in pig. Since PrV displays a strong tropism for mucous epithelial cells, we developed a kinetics study of PrV infection in the porcine PK15 epithelial cell line. To identify as completely as possible, viral and cellular genes regulated during infection, we simultaneously analyzed PrV and cellular transcriptome modifications using two microarrays i.e. a laboratory-made combined SLA/PrV microarray, consisting of probes for all PrV genes and for porcine genes contained in the Swine Leukocyte Antigen (SLA) complex, and the porcine generic Qiagen-NRSP8 oligonucleotide microarray. We confirmed the differential expression of a selected set of genes by qRT-PCR and flow cytometry.Entities:
Mesh:
Year: 2008 PMID: 18331636 PMCID: PMC2335119 DOI: 10.1186/1471-2164-9-123
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Map of the PrV transcriptome. The relative location of transcripts and designed amplicons are shown. UL and US regions of the PrV genome are represented in black while IR and TR regions are in pink. Transcripts corresponding to each gene are represented with arrows (coding region in orange and non-coding regions or introns in green). Amplicons are represented in blue on the genome. The name of each amplicon is written above the corresponding genome location. Size is measured in kb.
Figure 2PrV growth kinetics in PK15 cells. The PK15 cells were infected with PrV NIA3 at 20 MOI in HMS-M medium. PrV was titrated in the medium by plaque assay at different times pi (0, 4, 8, 12, 22, 26, 32 and 50 h pi). PrV titer was expressed as plaque forming units per ml (pfu/ml).
Figure 3Clusters of PrV gene expression levels identified by the k-means method. The average of normalized intensities for all mock-infected conditions and for each infected condition, centered (median) by genes were analyzed with the k-means method (three clusters). For each cluster, one graph and one clustering picture are represented. The graph shows the mean of the expression levels of all genes (x = Time; y = mean of levels of expression). The clustering picture depicts the mean of each gene expression level for all mock-infected time points and for each infected time point (x = Time; y = level of expression). The list of PrV amplicons belonging to each cluster, the list of the corresponding viral genes and the location of the corresponding proteins in virion structure (for amplicons that hybridize to a single transcript) are represented on the right. The names of the probes that are differentially expressed are represented in blue. To distinguish immediate early, early and late genes, early genes are underlined. All other genes are late genes except IE180 which is the only immediate early gene of PrV.
Number of viral and cellular probes differentially expressed at each time point.
| Probe set | Microarray | Probe subset | T0 | T1 | T2 | T4 | T8 | T12 |
| PrV | SLA/PrV | Probes homologous to a single transcript | 0 | 3 | 7 | 18 | 26 | 30 |
| Total | 0 | 3 | 13 | 34 | 52 | 58 | ||
| Pig | SLA/PrV | up-regulated SLA/Immune probes | 0 | 0 | 0 | 1 | 4 | 3 |
| down regulated SLA/Immune probes | 0 | 0 | 0 | 11 | 18 | 13 | ||
| up-regulated random probes | 1 | 0 | 2 | 4 | 15 | 11 | ||
| down-regulated random probes | 0 | 0 | 0 | 20 | 70 | 80 | ||
| Total | 1 | 0 | 2 | 36 | 107 | 107 | ||
| Qiagen- NRSP8 | up-regulated probes | ND* | 27 | 134 | 1262 | 3184 | ND* | |
| down-regulated probes | ND* | 4 | 47 | 1494 | 3509 | ND* | ||
| Total | ND* | 31 | 181 | 2756 | 6693 | ND* | ||
*ND: not determined
Viral probes and fold-change during infection kinetics.
| Amplicon name | Transcript name | Fold-change | Encoded protein and function* | Structural role* | |||||
| T0 | T1 | T2 | T4 | T8 | T12 | ||||
| ORF1 | ORF1 | - | - | - | - | - | unknown | virion | |
| UL54 | UL52/UL53/UL54 | - | - | - | - | - | - | ||
| UL53 | UL52/UL53 | - | - | 4.6 | 6.6 | 6.7 | 7.4 | ||
| UL52 | UL52 | - | - | - | 4.7 | 6.4 | 5.6 | DNA replication; primase subunit of UL5/UL8/UL52complex | nonstructural |
| UL51 | UL51 | - | - | - | - | - | - | viral egress | tegument |
| UL50 | UL50 | - | - | - | - | - | - | dUTPase | nonstructural |
| UL49.5 | UL49.5 | - | 4.4 | 6.4 | 9.0 | 10.4 | 13.5 | gN; immune evasion (TAP inhibitor) | envelope |
| UL49 | UL49.5/UL49 | - | - | - | - | - | - | ||
| UL48 | UL48 | - | - | - | - | - | - | VP16, α-TIF; gene regulation(transactivator); viral egress | tegument |
| UL47 | UL48/UL47 | - | - | - | - | 4.0 | 3.9 | ||
| UL46 | UL48/UL47/UL46 | - | - | - | - | - | - | VP11/12; unknown; tegument protein | |
| GII | UL28/UL27 | - | - | - | - | 6.7 | 6.3 | ||
| ICP18.5 | UL28 | - | - | - | - | - | 7.4 | ICP18,5; DNA cleavage and packaging; component of the UL15/UL28 terminase | capsid precursor |
| UL29 | UL29 | - | 6.0 | 9.2 | 10.6 | 8.9 | 10.9 | ICP8; DNA replication and recombination; binds ssDNA | nonstructural |
| UL30 | UL30 | - | - | 4.2 | - | - | - | DNA replication; DNA polymerase subunit of UL30/UL42 holoenzyme | nonstructural |
| UL31 | UL32/UL31 | - | - | - | 4.5 | 9.2 | 10.1 | ||
| UL32 | UL32 | - | - | - | - | 4.0 | 4.1 | DNA packaging; efficient localization of capsids to replication compartments | capsid precursor |
| UL33 | UL33 | - | - | - | - | 4.5 | 5.8 | DNA cleavage and packaging; associates with UL28 and UL15 | nonstructural |
| UL34 | UL33/UL34 | - | - | - | - | 6.1 | 5.0 | ||
| UL35 | UL33/UL34/UL35 | - | - | 5.6 | 7.1 | 9.5 | 9.5 | ||
| UL361 | UL36 | - | - | - | - | - | - | VP1/2; viral egress(capsid tegumentation); interacts with Ul37 and capsid | tegument |
| UL362 | UL36 | - | - | - | - | - | 3.8 | VP1/2; viral egress(capsid tegumentation); interacts with Ul37 and capsid | tegument |
| UL37 | UL37maj/UL37min | - | - | - | - | - | 5.0 | ||
| UL38 | UL38 | - | - | - | - | - | - | VP19c; minor capsid protein; UL38/UL18/UL18 triplex component | capsid |
| UL39 | UL39 | - | - | - | - | 4.4 | 6.3 | nucleotide synthesis; large subunit of ribonucleotide reductase | nonstructural |
| UL40 | UL39/UL40 | - | - | - | - | - | - | ||
| UL41 | UL41 | - | - | - | - | 4.2 | 6.8 | VHS, gene regulation; Rnase, degrades host and viral mRNAs | tegument |
| UL42 | UL42 | - | - | - | 6.3 | 6.9 | 4.6 | DNA replication; polymerase accessory subunit of UL30/UL42 holoenzyme | nonstructural |
| UL43 | UL43 | - | - | - | - | 4.1 | 6.2 | inhibits glycoprotein-mediated membrane fusion; type III membrane protein | envelope |
| GIIINIA3 | UL44 | - | - | - | 8.2 | 12.7 | 13.9 | gC; viral entry (virion attachment); type I membrane protein | envelope |
| ORF2NIA3 | UL24/UL25/UL26/UL26.5 | - | - | - | - | - | - | ||
| UL26NIA3 | UL24/UL25/UL26 | - | - | - | 6.7 | 8.3 | 7.6 | ||
| ORF1NIA3 | UL24/UL25 | 8.1 | 8.0 | ||||||
| UL25NIA3 | UL24/UL25 | - | - | - | 8.3 | 10.7 | 12.2 | ||
| UL24NIA3 | UL24 | - | - | - | 6.9 | 9.8 | 10.4 | unknown, type III membrane protein | unknown |
| TKNIA3 | UL23 | - | - | - | - | 5.0 | 6.8 | TK, nucleotide synthesis; thymidine kinase; selectively activates acyclovir | nonstructural |
| GHNIA3 | UL22 | - | - | 4.8 | 6.0 | 8.8 | 9.0 | gH; viral entry (fusion); cell-cell spread; type i membrane PT | envelope |
| UL21NIA3 | UL21 | - | - | - | - | 5.9 | 5.5 | unknown; capsid-associated tegument protein; interacts with UL16 | tegument |
| UL20NIA3 | UL20 | - | - | - | 3.8 | 5.3 | 7.3 | viral egress, type III membrane protein | unknown |
| UL191 | UL19maj/UL19min | - | - | - | 5.0 | 9.7 | 10.8 | ||
| UL192 | UL19maj/UL19min | - | - | 6.6 | 8.6 | 12.6 | 12.9 | ||
| UL18 | Ul19min/UL18 | - | - | - | 7.0 | 5.7 | 9.6 | ||
| UL15EX2 | UL15 (2nd exon) | - | - | 6.4 | 6.5 | 7.5 | 9.2 | DNA cleavage/encapsidation; terminase subunit of UL15/UL28 terminase6 | capsid precursor |
| UL17 | UL17 | - | - | - | - | - | - | DNA cleavage and encapsidation | inner capsid |
| UL16 | UL17/Ul16 | - | - | - | 4.5 | 6.2 | 5.0 | ||
| UL15EX12 | UL15 (1st exon) | - | - | - | - | 4.0 | 7.7 | DNA cleavage/encapsidation; terminase subunit of UL15/UL28 terminaseUL6 | capsid precursor |
| UL14 | UL14 | 6.1 | 6.1 | 9.8 | unknown | unknown | |||
| UL142 | UL14 | - | - | - | - | 6.3 | 7.8 | unknown | unknown |
| UL13 | UL14/UL13 | - | - | - | - | - | - | ||
| UL12 | UL14/UL13/UL12 | - | - | - | - | 3.7 | 5.3 | ||
| UL11 | UL14/UL13/UL12/UL11 | - | - | - | - | - | 6.0 | ||
| UL10 | UL10 | - | - | - | - | 6.6 | 6.1 | gM; inhibits glycoprotein-mediated membrane fusion; type III membrane protein | envelope |
| UL92 | UL9 | - | - | - | - | - | 4.1 | not found | non structural |
| UL8.5 | UL9/UL8.5 | - | - | - | 4.0 | - | - | ||
| UL8 | UL9/UL8.5/UL8 | - | - | - | - | - | - | ||
| UL7 | UL6/UL7 | - | - | 5.0 | 7.4 | 10.7 | 9.4 | ||
| UL6 | UL6 | - | - | 5.0 | 12.7 | 13.8 | 13.3 | capsid protein; portal protein; docking site for terminase | capsid |
| UL5 | UL5 | - | - | 4.3 | 6.3 | 8.7 | 5.9 | DNA replication; part of UL5/UL8/UL52 helicase/primase complex | nonstructural |
| UL4 | UL5/UL4 | - | - | - | - | 3.5 | 5.5 | unknown | |
| UL3.5 | UL1/UL2/UL3/UL3.5 | - | - | - | - | - | - | ||
| UL3 | UL1/UL2/UL3 | - | - | - | - | 5.1 | 6.5 | ||
| UL2 | UL1/UL2 | - | - | - | 4.2 | 5.4 | 5.4 | ||
| UL1 | UL1 | - | - | - | - | 6.5 | 7.3 | gL; viral entry (fusion); sell-sell spread | envelope |
| LLTE1 | LLT (1st exon) | - | - | - | 4.6 | 6.5 | 8.0 | not found | unknown |
| EP02 | EP0/LLT | - | - | - | - | - | - | ||
| EP01 | EP0/LLT | - | - | - | - | 6.3 | 4.7 | ||
| LLTI2 | LLT intron | - | - | - | - | 3.7 | 4.7 | ||
| LLTE21 | LLT (2nd exon) | - | - | - | - | - | - | not found | unknown |
| IEP2 | IE180 | - | - | - | 3.5 | - | - | ICP4; gene regulation (transactivator); immediate early protein | nonstructural |
| IEP1 | IE180 | - | - | - | - | - | - | ICP4; gene regulation (transactivator); immediate early protein | nonstructural |
| Ba5 | IE180/LLT (2nd exon) | 5.9 | 6.7 | 4.3 | |||||
| LLTE222 | LLT (2nd exon) | - | - | - | 6.8 | 8.9 | 8.2 | not found | unknown |
| RSP40 | US1 | - | 5.3 | 8.3 | 12.9 | 15.3 | 13.0 | RSP40/ICP22; unknown; HIV-1 homolog acts as regulator of gene expression | nonstructural |
| PKNIA3 | US3maj/US3min | - | - | - | - | 6.0 | 5.0 | PK, minor and major form of protein kinase; inhibits apoptosis | tegument |
| GXGG | US3maj/US3min/US4 | - | - | 6.5 | 9.1 | 10.6 | 11.0 | ||
| GP50GD | US6 | - | - | - | - | - | - | gD; viral entry, type I membrane protein | envelope |
| GP63GI | US6/US7 | - | - | - | 5.0 | 6.3 | 8.5 | ||
| GIGE | US8 | - | - | - | 4.0 | - | 4.3 | gE; cell-cell spread | envelope |
| 11K2 | US9/US8 | - | - | - | 9.0 | 10.0 | 10.4 | ||
| 28KNIA3 | US2 | - | - | - | 6.2 | 6.9 | 7.1 | 28K, tegument protein; membrane associated protein | tegument |
*gene function and structural role [1] are only specified for amplicons that hybridize to a single transcript.
- gene not found differentially expressed between PrV infected and mock-infected cells
Figure 4Clusters of PK15 gene expression levels identified by the k-means method. The expression levels of genes that are differentially expressed between infected and mock-infected cells at each time point are analyzed by the k-means method (three clusters). Averages of normalized intensities for all mock-infected conditions and for each infected condition were centered (median) by genes. For each cluster, one graph and one clustering picture are represented. The graph shows the mean of the expression levels of all genes (x = Time; y = mean of levels of expression) and the clustering picture depicts the mean of each gene expression level for all mock-infected time points and for each infected time point (x = Time; y = level of expression).
Biological processes associated with differentially expressed cellular genes.
| Biological process* | Time pi (h)§ | |||
| T1 | T2 | T4 | T8 | |
| Protein metabolism and modification (BP00060) | 1 | 26 | 311 | 768 |
| Nucleoside, nucleotide and nucleic acid metabolism (BP00031) | 3 | 22 | 321 | 702 |
| Developmental processes (BP00193) | 8 | 16 | 224 | 487 |
| Signal transduction (BP00102) | 5 | 14 | 337 | 737 |
| Transport (BP00141) | 1 | 13 | 139 | 308 |
| Cell cycle (BP00203) | 2 | 12 | 124 | 262 |
| Immunity and defense (BP00148) | 1 | 11 | 120 | 309 |
| Intracellular protein traffic (BP00125) | 2 | 10 | 115 | 266 |
| Cell structure and motility (BP00285) | 2 | 7 | 119 | 279 |
| Cell proliferation and differentiation (BP00224) | 2 | 6 | 100 | 215 |
| Other metabolism (BP00289) | 2 | 6 | 71 | 159 |
| Apoptosis (BP00179) | 0 | 6 | 61 | 132 |
| Cell adhesion (BP00124) | 0 | 5 | 68 | 136 |
| Carbohydrate metabolism (BP00001) | 0 | 3 | 67 | 165 |
| Amino acid metabolism (BP00013) | 1 | 3 | 36 | 70 |
| Protein targeting and localization (BP00137) | 1 | 3 | 25 | 65 |
| Blood circulation and gas exchange (BP00209) | 0 | 3 | 9 | 26 |
| Oncogenesis (BP00281) | 0 | 2 | 57 | 116 |
| Neuronal activities (BP00166) | 1 | 2 | 50 | 106 |
| Lipid, fatty acid and steroid metabolism (BP00019) | 0 | 1 | 71 | 183 |
| Electron transport (BP00076) | 0 | 1 | 32 | 69 |
| Muscle contraction (BP00173) | 0 | 1 | 26 | 55 |
| Sensory perception (BP00182) | 0 | 1 | 25 | 60 |
| Coenzyme and prosthetic group metabolism (BP00081) | 0 | 1 | 19 | 46 |
| Miscellaneous (BP00211) | 0 | 1 | 12 | 30 |
| Phosphate metabolism (BP00095) | 0 | 1 | 8 | 27 |
| Sulfur metabolism (BP00101) | 0 | 1 | 8 | 22 |
| Nitrogen metabolism (BP00090) | 0 | 1 | 5 | 5 |
| Non-vertebrate process (BP00301) | 0 | 0 | 1 | 3 |
| Homeostasis (BP00267) | 0 | 0 | 16 | 49 |
| Biological process unclassified (BP00216) | 7 | 40 | 549 | 1232 |
| Number of analyzed genes | 24 | 141 | 1272 | 4458 |
§ The number of genes from the Qiagen_NRSP8 microarray found in Panther database is reported at each time point for each biological process.
*The same focus gene may exist in different biological processes.
Top functions associated with significant networks identified by IPA and number of focus genes at each time point.
| Top functions | Time | |||
| T1 | T2 | T4 | T8 | |
| Gene Expression | 9 | 12 | 178 | 297 |
| Molecular Transport | 9 | - | 81 | 372 |
| Drug Metabolism | 9 | - | 31 | 83 |
| Cancer | - | 47 | 386 | 357 |
| Connective Tissue Development and Function | - | 27 | 103 | 152 |
| Cell Cycle | - | 24 | 246 | 432 |
| Cellular Development | - | 23 | 144 | 64 |
| Cell Death | - | 23 | 141 | 205 |
| Cell Morphology | - | 23 | 91 | 58 |
| Cellular Movement | - | 15 | 92 | 125 |
| Cellular Assembly and Organization | - | 15 | 82 | 358 |
| Post-Translational Modification | - | 13 | 75 | 79 |
| Small Molecule Biochemistry | - | 13 | 64 | 324 |
| Amino Acid Metabolism | - | 13 | 56 | 219 |
| Neurological Disease | - | 12 | 59 | 147 |
| Organismal Injury and Abnormalities | - | 12 | 30 | 56 |
| Cellular Growth and Proliferation | - | 11 | 93 | 114 |
| Connective Tissue Disorders | - | 11 | 15 | 21 |
| Cell Signaling | - | - | 223 | 662 |
| DNA Replication Recombination and Repair | - | - | 183 | 194 |
| Genetic Disorder | - | - | 128 | 218 |
| Nervous System Development and Function | - | - | 98 | 166 |
| Hematological Disease | - | - | 92 | 89 |
| Protein Synthesis | - | - | 88 | 204 |
| Dermatological Diseases and Conditions | - | - | 82 | 175 |
| Hematological System Development and Function | - | - | 81 | 116 |
| Lipid Metabolism | - | - | 79 | 363 |
| Cell-To-Cell Signaling and Interaction | - | - | 76 | 122 |
| Skeletal and Muscular Disorders | - | - | 76 | 33 |
| Immune Response | - | - | 71 | 246 |
| Cardiovascular Disease | - | - | 70 | 80 |
| Cellular Function and Maintenance | - | - | 61 | 263 |
| Embryonic Development | - | - | 54 | 180 |
| Endocrine System Development and Function | - | - | 53 | 62 |
| Immunological Disease | - | - | 44 | 54 |
| RNA Post-Transcriptional Modification | - | - | 43 | 122 |
| Nucleic Acid Metabolism | - | - | 39 | 130 |
| Reproductive System Development and Function | - | - | 35 | 26 |
| Tissue Development | - | - | 34 | 73 |
| Protein Trafficking | - | - | 34 | 63 |
| Protein Folding | - | - | 32 | 31 |
| Carbohydrate Metabolism | - | - | 31 | 136 |
| Cardiovascular System Development and Function | - | - | 31 | 127 |
| Organismal Development | - | - | 29 | 30 |
| Cellular Compromise | - | - | 28 | 96 |
| Organ Morphology | - | - | 28 | 91 |
| Vitamin and Mineral Metabolism | - | - | 27 | 61 |
| Skeletal and Muscular System Development and Function | - | - | 25 | 33 |
| Developmental Disorder | - | - | 18 | 33 |
| Inflammatory Disease | - | - | 16 | 95 |
| Nutritional Disease | - | - | 16 | 30 |
| Infectious Disease | - | - | 14 | 65 |
| Metabolic Disease | - | - | 12 | 89 |
| Viral Function | - | - | 61 | - |
| Reproductive System Disease | - | - | 48 | - |
| Ophthalmic Disease | - | - | 32 | - |
| Hair and Skin Development and Function | - | - | 31 | - |
| Organ Development | - | - | 31 | - |
| Cardiac Fibrosis | - | - | 30 | - |
| Viral Infection | - | - | 30 | - |
| Cardiac Enlargement | - | - | 28 | - |
| DNA Replication | - | - | 20 | - |
| Cardiac Pulmonary Embolism | - | - | 17 | - |
| Dermatological Diseases and Condition | - | - | 17 | - |
| Cardiac Necrosis/Cell Death | - | - | 16 | - |
| Digestive System Development and Function | - | - | 16 | - |
| Hepatic System Disease | - | - | 14 | - |
| Tumor Morphology | - | - | 13 | - |
| Protein Degradation | - | - | - | 119 |
| Energy Production | - | - | - | 84 |
| Gastrointestinal Disease | - | - | - | 65 |
| Behavior | - | - | - | 61 |
| Immune and Lymphatic System Development and Function | - | - | - | 61 |
| Renal Necrosis/Cell Death | - | - | - | 33 |
| Renal and Urological System Development and Function | - | - | - | 32 |
| Endocrine System Disorders | - | - | - | 31 |
| Cardiac Hypertrophy | - | - | - | 30 |
| Organismal Survival | - | - | - | 28 |
| Free Radical Scavenging | - | - | - | 27 |
| Respiratory System Development and Function | - | - | - | 25 |
| Tissue Morphology | - | - | - | 23 |
| Hepatic System Development and Function | - | - | - | 21 |
| Focus genes | 12 | 98 | 1474 | 2887 |
*The same focus gene may exist in different top functions.
§ The number of focus genes from the Qiagen_NRSP8 microarray is reported at each time point for each top function.
Subset of differentially expressed cellular genes at each time point.
| SS00013127 | HLA-A | NM_002116 | NS | - | - | - | -4.6 | NS | Qiagen-NRSP8 | |
| SS00001303 | HLA-A | NM_002116 | NS | - | - | - | -3.8 | NS | Qiagen-NRSP8 | |
| SCAN0007.O.20 | SLA Ia | NM_002116 | - | - | - | -4.9 | -4.6 | -4.5 | SLA/PRV | |
| SCAN0032.G.07 | SLA Ia | NM_002116 | - | - | - | - | -4.0 | - | SLA/PRV | |
| SCAN0010.J.21 | SLA Ia | NM_002116 | - | - | - | - | - | -5.9 | SLA/PRV | |
| SCAA0099.O.04 | SLA-7 | NM_002116 | - | - | - | -3.5 | -3.6 | - | SLA/PRV | |
| SS00000703 | PSMB8 | NM_148919 | NS | - | - | 5.5 | 7.8 | NS | Qiagen-NRSP8 | |
| SCAC0037.O.09 | TAP1 | NM_000593 | - | - | - | - | 3.9 | - | SLA/PRV | |
| SS00010012 | TAP1 | NM_000593 | - | - | - | -7.8 | NS | Qiagen-NRSP8 | ||
| SS00002173 | TAP2 | NM_000544 | NS | - | - | -6.9 | - | NS | Qiagen-NRSP8 | |
| SS00010176 | MICB | NM_005931 | NS | - | - | 11.1 | 11.3 | NS | Qiagen-NRSP8 | |
| SS00000697 | HLA-DMB | NM_002118 | NS | - | - | - | -7.7 | NS | Qiagen-NRSP8 | |
| SS00000661 | HLA-DOA | NM_002119 | NS | - | - | - | 5.2 | NS | Qiagen-NRSP8 | |
| SS00000973 | HLA-DQA1 | NM_002122 | NS | - | - | - | 5.2 | NS | Qiagen-NRSP8 | |
| SCAB0137.B.15 | HLA-DOB | NM_002120 | - | - | - | -4.0 | - | - | SLA/PRV | |
| SCAC0044.H.08 | HLA-DMB | NM_002118 | - | - | - | -4.6 | - | - | SLA/PRV | |
| SS00000824 | CIITA | NM_000246 | NS | - | - | - | 3.3 | NS | Qiagen-NRSP8 | |
| SS00010182 | CD4 | NM_000616 | NS | - | 5.1 | 14.6 | 14.1 | NS | Qiagen-NRSP8 | |
| SS00009986 | CD69 | NM_001781 | NS | - | - | -3.1 | -5.9 | NS | Qiagen-NRSP8 | |
| SS00006217 | CLEC2L | XM_498242 | NS | - | 3.2 | 11.8 | 16.1 | NS | Qiagen-NRSP8 | |
| SS00009653 | CLEC5A | NM_013252 | NS | - | - | -4.0 | -6.9 | NS | Qiagen-NRSP8 | |
| SS00002913 | IK | NM_006083 | NS | - | - | - | 5.0 | NS | Qiagen-NRSP8 | |
| SS00010183 | ICAM1 | NM_000201 | NS | - | - | -4.2 | -9.2 | NS | Qiagen-NRSP8 | |
| SS00003797 | IFNAR2 | NM_207585 | NS | - | - | 3.5 | 7.9 | NS | Qiagen-NRSP8 | |
| SS00010797 | IFNGR2 | NM_005534 | NS | - | - | - | -6.1 | NS | Qiagen-NRSP8 | |
| SS00002396 | IRF1 | NM_002198 | NS | - | - | -5.0 | -9.3 | NS | Qiagen-NRSP8 | |
| SS00009562 | IRF2 | NM_002199 | NS | - | - | -4.4 | -10.8 | NS | Qiagen-NRSP8 | |
| SS00000183 | IRF3 | NM_001571 | NS | - | - | - | -3.9 | NS | Qiagen-NRSP8 | |
| SS00003318 | IRF5 | NM_032643 | NS | - | - | -3.5 | -7.9 | NS | Qiagen-NRSP8 | |
| SS00000904 | IFNA6 | NM_021002 | NS | - | - | - | -7.2 | NS | Qiagen-NRSP8 | |
| SS00010817 | IFI6 | NM_002038 | NS | - | - | 6.5 | 12.5 | NS | Qiagen-NRSP8 | |
| SS00010811 | IFI30 | NM_006332 | NS | - | - | - | -6.1 | NS | Qiagen-NRSP8 | |
| SS00001608 | ISGF3G | NM_006084 | NS | - | - | - | 3.9 | NS | Qiagen-NRSP8 | |
| SS00009843 | IL12A | NM_000882 | NS | - | - | -3.3 | -17.1 | NS | Qiagen-NRSP8 | |
| SS00009841 | IL12B | NM_002187 | NS | - | - | -7.9 | -17.1 | NS | Qiagen-NRSP8 | |
| SS00008021 | TLR8 | NM_016610 | NS | - | - | -4.6 | -5.9 | NS | Qiagen-NRSP8 | |
| SCAA0015.B.22 | PPIA | NM_021130.3 | - | - | - | -3.9 | -4.8 | -4.8 | SLA/PRV | |
| SCAU0001.B.05 | PPIA | NM_021130.3 | - | - | - | -3.6 | -4.3 | -4.7 | SLA/PRV | |
| SS00003892 | PPIL1 | NM_016059 | NS | - | - | - | 3.2 | NS | Qiagen-NRSP8 | |
| SS00001759 | PPIL2 | NM_148176 | NS | - | - | - | 4.1 | NS | Qiagen-NRSP8 | |
| SS00001178 | PPIF | NM_005729 | NS | - | - | - | -3.8 | NS | Qiagen-NRSP8 | |
| SS00001241 | PPIG | NM_004792 | NS | - | - | - | -4.3 | NS | Qiagen-NRSP8 | |
| SS00005782 | PPIH | NM_006347 | NS | - | - | - | 5.1 | NS | Qiagen-NRSP8 | |
| SS00006083 | FKBP3 | NM_002013 | NS | - | - | - | -8.3 | NS | Qiagen-NRSP8 | |
| SS00002702 | FKBP4 | NM_002014 | NS | - | 3.6 | 13.0 | 14.3 | NS | Qiagen-NRSP8 | |
| SS00003686 | BNIP1 | NM_001205 | NS | - | - | - | -6.1 | NS | Qiagen-NRSP8 | |
| SS00000546 | BAK1 | NM_001188 | NS | - | - | - | -4.3 | NS | Qiagen-NRSP8 | |
| SS00010935 | BCLAF1 | NM_014739 | NS | - | -4.0 | -4.6 | -6.6 | NS | Qiagen-NRSP8 | |
| SS00001150 | BCL2L1 | NM_138578 | NS | - | - | -3.4 | -6.5 | NS | Qiagen-NRSP8 | |
| SS00005026 | BCL2L14 | NM_138723 | NS | - | - | - | -5.8 | NS | Qiagen-NRSP8 | |
| SS00000872 | CASP1 | NM_033293 | NS | - | - | 3.6 | 5.0 | NS | Qiagen-NRSP8 | |
| SS00000520 | CASP3 | NM_032991 | NS | - | - | - | -0.7 | NS | Qiagen-NRSP8 | |
| SS00004783 | CASP7 | NM_001227 | NS | - | - | - | 6.7 | NS | Qiagen-NRSP8 | |
| SS00003624 | CARD6 | NM_032587 | NS | - | - | 3.5 | 6.6 | NS | Qiagen-NRSP8 | |
| SS00000561 | DDX58 | NM_014314 | NS | - | -3.1 | -4.3 | -8.3 | NS | Qiagen-NRSP8 | |
| SS00000329 | FAF1 | NM_007051 | NS | - | - | - | 5.8 | NS | Qiagen-NRSP8 | |
| SS00012494 | FAIM2 | NM_012306 | NS | - | - | -4.6 | -10.7 | NS | Qiagen-NRSP8 | |
| SS00000384 | EIF2A | NM_032025 | NS | - | - | 3.7 | 7.1 | NS | Qiagen-NRSP8 | |
| SS00008645 | XBP1 | NM_005080 | NS | - | - | - | -6.4 | NS | Qiagen-NRSP8 | |
| SS00004223 | ATF4 | NM_182810 | NS | - | - | - | -4.1 | NS | Qiagen-NRSP8 | |
| SS00001308 | HSPA8 | NM_006597 | NS | - | - | - | 3.6 | NS | Qiagen-NRSP8 | |
| SCAB0073.K.18 | HIST1H2BK | NM_080593 | - | - | - | -3.9 | -6.8 | -4.4 | SLA/PRV | |
| SCAA0122.E.09 | HIST1H2AL | NM_003511 | - | - | - | -3.9 | -6.0 | -3.7 | SLA/PRV | |
| SCAB0057.M.21 | HIST1H4J | NM_021968 | - | - | - | -5.1 | -4.4 | -4.0 | SLA/PRV | |
| SCAB0015.G.08 | HIST3H2BB | NM_021968 | - | - | - | - | -4.2 | -5.4 | SLA/PRV | |
| SS00005067 | HDAC2 | NM_001527 | NS | - | 4.6 | 8.3 | 9.1 | NS | Qiagen-NRSP8 | |
| SS00004784 | HDAC3 | NM_003883 | NS | - | - | -5.5 | -10.9 | NS | Qiagen-NRSP8 | |
| SS00007434 | HDAC6 | NM_006044 | NS | - | - | -3.7 | -8.4 | NS | Qiagen-NRSP8 | |
| SS00003586 | HDAC9 | NM_014707 | NS | - | -3.5 | -4.8 | -10.6 | NS | Qiagen-NRSP8 | |
| SS00004682 | HDAC10 | NM_032019 | NS | - | - | - | 3.9 | NS | Qiagen-NRSP8 | |
| SS00007084 | STAT1 | NM_007315 | NS | - | - | - | 7.6 | NS | Qiagen-NRSP8 | |
| SS00008286 | STAT3 | NM_139276 | NS | - | - | - | -4.4 | NS | Qiagen-NRSP8 | |
| SS00008435 | STAT5B | NM_012448 | NS | - | - | -5.3 | -9.9 | NS | Qiagen-NRSP8 | |
| SS00004427 | STAT6 | NM_003153 | NS | - | - | - | -4.6 | NS | Qiagen-NRSP8 | |
| SS00003440 | ACTC1 | NM_005159 | NS | - | - | - | -8.9 | NS | Qiagen-NRSP8 | |
| SS00013114 | ACTG1 | NM_001614 | NS | 3.3 | 6.9 | 19.4 | 18.2 | NS | Qiagen-NRSP8 | |
| SS00002774 | ACTL6A | NM_004301 | NS | - | - | - | 3.6 | NS | Qiagen-NRSP8 | |
| SS00005476 | ACTRT2 | NM_080431 | NS | - | - | - | -7.2 | NS | Qiagen-NRSP8 | |
| SS00007431 | ACTA4 | NM_00492 | NS | - | - | -3.7 | -3.9 | NS | Qiagen-NRSP8 | |
| SS00011046 | MYO1D | NM_015194 | NS | - | - | -4.7 | -10.2 | NS | Qiagen-NRSP8 | |
| SS00007818 | MYO5A | NM_000259 | NS | - | - | -3.7 | -9.8 | NS | Qiagen-NRSP8 | |
* ER: Endoplasmic Reticulum
NS: Not Studied
-: not differentially express
Cellular gene expression study by qRT-PCR.
| 1.6 | 2.3 | 2.6 | 14.7 | 14.5 | 10.5 | |
| 1.2 | 1.1 | 0.7 | 0.2 | 0.1 | 0.1 | |
| 0.7 | 0.9 | - | - | 0.6 | 0.5 | |
| - | - | - | - | 0.8 | 0.6 | |
| 1.2 | 1.2 | 1.0 | 0.8 | 0.5 | 0.4 | |
| 0.8 | 0.6 | 0.6 | 0.7 | 0.3 | 0.3 | |
| - | 0.6 | 0.7 | 0.6 | 0.3 | 0.2 | |
- - no detected difference between two samples
- *: mock-infected
- **: PrV infected
Figure 5SLA I cell surface decrease on PrV infected PK15 cells. Histogram overlays of MHC class I expression detected by the mAb PT85A are shown. The number in red represents the percent mean fluorescence intensity [(mean channel fluorescence of the infected sample at 8 h pi/mean channel fluorescence of the mock-infected cells at 8 h pi) × 100]. The results represent one of three representative experiments.
Figure 6Hybridization scheme of the SLA/PrV and the Qiagen-NRSP8 microarrays. A Hybridization scheme of the SLA/PrV microarrays. Forty-eight hybridizations corresponding to 24 PrV/SLA slides were hybridized (two arrays per slide, see Methods). B Hybridization scheme of the Qiagen-NRSP8 microarrays. Thirty-two Qiagen-NRSP8 slides were hybridized. Each labeled target is represented by its dye Cy3 or Cy5. Each arrow linking Cy3 to Cy5 represents one hybridization on one array.
Sequence of primers for qRT-PCR.
| Target | Oligo | Sequence | Size(bp) |
| RPL32 | forward | TGCTCTCAGACCCCTTGTGAAG | 22 |
| reverse | TTTCCGCCAGTTCCGCTTA | 19 | |
| SLAIa | forward | CATCATTGTTGGCCTGGTTC | 20 |
| reverse | CCTTTTTCACCTGAGCGC | 18 | |
| TAP1 | forward | CCAGTATCTCAGGGATGTTGCTG | 23 |
| reverse | CGCTGCTTATAGCCCCACC | 19 | |
| TAP2 | forward | TGTTGGGTGAGACACTAATCCCTTA | 25 |
| reverse | CAAAGGCATCAGGGTCAAAATC | 22 | |
| PSMB9 | forward | GCGCTTCACCACAAATGCTA | 20 |
| reverse | TCCACACCAGCAGCTGTAATG | 21 | |
| PSMB8 | forward | TACCTGCTTGGCACCATGTCT | 21 |
| reverse | AGTACAACCTGCACTCCTTGGC | 22 | |
| PPIA | forward | GTCTCCTTCGAGCTGTTTGCA | 21 |
| reverse | CCAAATCCTTTCTCCCCAGTG | 21 | |
| TNF | forward | CCCAAGGACTCAGATCATCGTC | 22 |
| reverse | AGCTGTCCCTCGGCTTTGA | 19 |